Articolul precedent |
Articolul urmator |
320 8 |
Ultima descărcare din IBN: 2024-04-23 21:16 |
Căutarea după subiecte similare conform CZU |
616.72-002.77-053.2-085:575.2 (1) |
Нервная система. Невропатология. Неврология (491) |
Общая генетика. Общая цитогенетика. Иммуногенетика. Эволюционное учение. Видообразование. Филогенез (430) |
SM ISO690:2012 IACOMI, Vladimir, REVENCO, Ninel, EREMCIUC, Rodica, FOCA, Silvia-Gabriela, CRACEA (DRUŞCA), Angela, GAIDARJI, Olga. Monitorizarea terapiei cu metotrexat în artrita juvenilă idiopatică: variații farmacogenetice . In: Managementul interdisciplinar al copilului, Ed. Ediţia a 5-a, 13 mai 2022, Chişinău. Chişinău: Tipografia Taicom, 2022, Ediţia a 5-a, pp. 17-23. ISBN 978-9975-58-274-2. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Managementul interdisciplinar al copilului Ediţia a 5-a, 2022 |
||||||
Conferința "Managementul interdisciplinar al copilului" Ediţia a 5-a, Chişinău, Moldova, 13 mai 2022 | ||||||
|
||||||
CZU: 616.72-002.77-053.2-085:575.2 | ||||||
Pag. 17-23 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
The treatment of the child with juvenile idiopathic arthritis includes many non-pharmacological and pharmacological variables that are interspersed both at the onset and on the escalation stages of the medication. For both actors, the patient and the doctor, the therapeutic efficacy that increases the quality of life of this child is essential. Genetic sus-ceptibility to drug efficacy has been shown to be the technological outbreak that could currently guide the practitioner in choosing a personified therapy. For many decades, methotrexate is the world’s gold standard for both adults with rheumatoid arthritis and children with juvenile idiopathic arthritis. Unfortunately, a considerable number of patients do not achieve an adequate therapeutic response. Folate antagonist, increased plasma clearance, low therapeutic dose - these are key features that induce the need to study its biomolecular effect and predictors of administration outcome. Multiple serological biomarkers are used to elucidate its toxic and ineffective potential, one of which is the enzymes involved at the cellular level in folate metabolism. Methylenetetrahydrofolate reducedase, a regulatory enzyme that participates in the primary metabolic stage is the subject of study for several centers dealing with this topic. The phar-macological response of methotrexate is of paramount importance to mutations in the gene encoding this enzyme. The pharmacogenomic impact of these changes is the reduction of early childhood disability due to the inefficiency and subclinical toxicity of methotrexate in children with juvenile idiopathic arthritis. Finally, we review the results of the pharmacogenetics study at the clinic we represent. |
||||||
Cuvinte-cheie methotrexate, arthritis, Gene, efficacy, toxicity, folate |
||||||
|